Kéramidas Michelle, de Fraipont Florence, Karageorgis Anastassia, Moisan Anaïck, Persoons Virginie, Richard Marie-Jeanne, Coll Jean-Luc, Rome Claire
Stem Cell Res Ther. 2013 Apr 29;4(2):41. doi: 10.1186/scrt195.
Understanding the multiple biological functions played by human mesenchymal stem cells (hMSCs) as well as their development as therapeutics in regenerative medicine or in cancer treatment are major fields of research. Indeed, it has been established that hMSCs play a central role in the pathogenesis and progression of tumours, but their impact on tumour growth remains controversial.
In this study, we investigated the influence of hMSCs on the growth of pre-established tumours. We engrafted nude mice with luciferase-positive mouse adenocarcinoma cells (TSA-Luc+) to obtain subcutaneous or lung tumours. When tumour presence was confirmed by non-invasive bioluminescence imaging, hMSCs were injected into the periphery of the SC tumours or delivered by systemic intravenous injection in mice bearing either SC tumours or lung metastasis.
Regardless of the tumour model and mode of hMSC injection, hMSC administration was always associated with decreased tumour growth due to an inhibition of tumour cell proliferation, likely resulting from deep modifications of the tumour angiogenesis. Indeed, we established that although hMSCs can induce the formation of new blood vessels in a non-tumoural cellulose sponge model in mice, they do not modify the overall amount of haemoglobin delivered into the SC tumours or lung metastasis. We observed that these tumour vessels were reduced in number but were longer.
Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.
了解人间充质干细胞(hMSCs)所发挥的多种生物学功能及其作为再生医学或癌症治疗中的治疗手段的发展情况是主要研究领域。事实上,已经证实hMSCs在肿瘤的发病机制和进展中起核心作用,但其对肿瘤生长的影响仍存在争议。
在本研究中,我们调查了hMSCs对预先建立的肿瘤生长的影响。我们将荧光素酶阳性小鼠腺癌细胞(TSA-Luc+)移植到裸鼠体内,以获得皮下或肺部肿瘤。当通过非侵入性生物发光成像确认肿瘤存在时,将hMSCs注射到皮下肿瘤的周边,或通过全身静脉注射给予患有皮下肿瘤或肺转移的小鼠。
无论肿瘤模型和hMSCs注射方式如何,hMSCs给药总是与肿瘤生长减少相关,这是由于肿瘤细胞增殖受到抑制,这可能是肿瘤血管生成发生深刻改变的结果。事实上,我们证实,虽然hMSCs可以在小鼠的非肿瘤性纤维素海绵模型中诱导新血管的形成,但它们不会改变输送到皮下肿瘤或肺转移中的血红蛋白总量。我们观察到这些肿瘤血管数量减少但更长。
我们的结果表明,注射hMSCs可减少小鼠实体瘤的生长并改变肿瘤脉管系统,这证实hMSCs可能是用于治疗预先建立的肿瘤的有趣选择。